The 13-valent pneumococcal conjugated vaccine introduction in subjects aged> 50 years: the result of a Health Technology Assessment

The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA) : What is the future of pneumococcal conjugate vaccination in elderly?

Van Werkhoven, Cornelis H.
Bonten, Marc Jm

September 2015

Pneumococcal community-acquired pneumonia (PCAP) and invasive pneumococcal disease (IPD) are importa...

Vaccination status impact on mortality and hospital re-admission for CAP in elderly: a regional italian experience

Baldo, Vincenzo
Cocchio, Silvia
Gallo, T.
Furlan, Patrizia
Bertoncello, Chiara
Baldovin, Tatjana

January 2016

The aim of the study was to evaluate mortality and rehospitalizations after a first episode of Commu...

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Jackson, Lisa A.
Gurtman, Alejandra
Rice, Kathryn
Pauksens, Karlis
Greenberg, Richard N.
Jones, Thomas R.
Scott, Daniel A.
Emini, Emilio A.
Gruber, William C.
Schmoele-Thoma, Beate

August 2013

AbstractBackgroundThe currently recommended single dose of the 23-valent pneumococcal free polysacch...

The 13-valent pneumococcal conjugated vaccine introduction in subjects aged> 50 years: the result of a Health Technology Assessment

De Waure, Chiara (ORCID:0000-0002-4346-1494)
Specchia, Maria Lucia (ORCID:0000-0002-3859-4591)
Di Pietro, Maria Luisa (ORCID:0000-0002-3893-8788)
Capizzi, Silvio
Cadeddu, Chiara (ORCID:0000-0003-0149-1078)
Di Nardo, Francesco
Ferriero, Anna Maria
Veneziano, Maria Assunta
Gualano, Maria Rosaria
Nicolotti, Nicola
Sferrazza, Antonella
Refolo, Pietro (ORCID:0000-0003-1055-160X)
Gliubizzi, Maria Daniela
La Torre, Giuseppe
Ricciardi, Gualtiero (ORCID:0000-0002-5655-688X)

January 2013

Streptococcus pneumoniae (Spn) is a common cause of Community-Acquired Pneumonia (CAP) and Invasive ...

Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ

Starla Hayward
Lou Ann Thompson
Andrea McEachern

April 2016

Pneumonia infection is a significant cause of morbidity and mortality worldwide. In addition to the ...

The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly : Exploratory analysis of the CAPiTA trial

Huijts, S. M.
Coenjaerts, F. E.J.
Bolkenbaas, M.
van Werkhoven, C. H.
Grobbee, D. E.
Bonten, M. J.M.

July 2018

Objectives: Our objective was to evaluate whether vaccination with the 13-valent pneumococcal conjug...

Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?

Torres, A.
Bonanni, P.
Hryniewicz, W.
Moutschen, Michel
Reinert, R. R.
Welte, T.

January 2014

Individuals /=50 years of age, as well as those with other specific risk factors, are especially vul...

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

van Deursen, Anna M. M.
van Houten, Marlies A
Webber, Chris
Patton, Michael
Scott, Daniel A.
Patterson, Scott
Sidhu, Mohinder
Drews, Wayne
Gruber, William C.
Emini, Emilio A.
Grobbee, Diederick E.
Bonten, Marc J. M.
Sanders, Elisabeth A. M.

September 2017

Background. In the randomized controlled Community-Acquired Pneumonia Immunization Trial in Adults (...

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

van Deursen, Anna M. M.
van Houten, Marlies A
Webber, Chris
Patton, Michael
Scott, Daniel A.
Patterson, Scott
Sidhu, Mohinder
Drews, Wayne
Gruber, William C.
Emini, Emilio A.
Grobbee, Diederick E.
Bonten, Marc J. M.
Sanders, Elisabeth A. M.

September 2017

Background. In the randomized controlled Community-Acquired Pneumonia Immunization Trial in Adults (...

Pneumococcal disease and vaccinations in older adults

van Deursen, A.M.M.

June 2018

Streptococcus pneumoniae is the most frequently detected human pathogen in respiratory infections wi...

Pneumococcal disease and vaccinations in older adults

van Deursen, A.M.M.

June 2018

Streptococcus pneumoniae is the most frequently detected human pathogen in respiratory infections wi...

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

Bonten, M. J M
Huijts, S. M.
Bolkenbaas, M.
Webber, C.
Patterson, S.
Gault, S.
Van Werkhoven, C. H.
Van Deursen, A. M M
Sanders, E. A M
Verheij, T. J M
Patton, M.
McDonough, A.
Moradoghli-Haftvani, A.
Smith, H.
Mellelieu, T.
Pride, M. W.
Crowther, G.
Schmoele-Thoma, B.
Scott, D. A.
Jansen, K. U.
Lobatto, R.
Oosterman, B.
Visser, N.
Caspers, E.
Smorenburg, A.
Emini, E. A.
Gruber, W. C.
Grobbee, D. E.

January 2015

BACKGROUND Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal disease in infants, b...

Prevenar 13®, a pneumococcal conjugate vaccine for the prevention of pneumococcal infections in adults at risk

Moutschen, Michel

January 2016

peer reviewedPneumococcal infections remain a major public health issue in aging people. The recent ...

Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation.

F. Ansaldi
D. d. Florentiis
P. Canepa
A. Ceravolo
E. Rappazzo
R. Iudici
M. Martini
G. Botti
A. Orsi
G. Icardi
P. Durando

January 2013

A serial cross-sectional study of nasopharyngeal carriage among adults aged 60 y or over was conduct...

The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA) : What is the future of pneumococcal conjugate vaccination in elderly?

Van Werkhoven, Cornelis H.
Bonten, Marc Jm

September 2015

Pneumococcal community-acquired pneumonia (PCAP) and invasive pneumococcal disease (IPD) are importa...

The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA) : What is the future of pneumococcal conjugate vaccination in elderly?

Van Werkhoven, Cornelis H.
Bonten, Marc Jm

September 2015

Pneumococcal community-acquired pneumonia (PCAP) and invasive pneumococcal disease (IPD) are importa...

Vaccination status impact on mortality and hospital re-admission for CAP in elderly: a regional italian experience

Baldo, Vincenzo
Cocchio, Silvia
Gallo, T.
Furlan, Patrizia
Bertoncello, Chiara
Baldovin, Tatjana

January 2016

The aim of the study was to evaluate mortality and rehospitalizations after a first episode of Commu...

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Jackson, Lisa A.
Gurtman, Alejandra
Rice, Kathryn
Pauksens, Karlis
Greenberg, Richard N.
Jones, Thomas R.
Scott, Daniel A.
Emini, Emilio A.
Gruber, William C.
Schmoele-Thoma, Beate

August 2013

AbstractBackgroundThe currently recommended single dose of the 23-valent pneumococcal free polysacch...

The 13-valent pneumococcal conjugated vaccine introduction in subjects aged> 50 years: the result of a Health Technology Assessment

De Waure, Chiara (ORCID:0000-0002-4346-1494)
Specchia, Maria Lucia (ORCID:0000-0002-3859-4591)
Di Pietro, Maria Luisa (ORCID:0000-0002-3893-8788)
Capizzi, Silvio
Cadeddu, Chiara (ORCID:0000-0003-0149-1078)
Di Nardo, Francesco
Ferriero, Anna Maria
Veneziano, Maria Assunta
Gualano, Maria Rosaria
Nicolotti, Nicola
Sferrazza, Antonella
Refolo, Pietro (ORCID:0000-0003-1055-160X)
Gliubizzi, Maria Daniela
La Torre, Giuseppe
Ricciardi, Gualtiero (ORCID:0000-0002-5655-688X)

January 2013

Streptococcus pneumoniae (Spn) is a common cause of Community-Acquired Pneumonia (CAP) and Invasive ...

Is 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Combined With 23-Valent Pneumococcal Polysaccharide Vaccine (PPSV23) Superior to PPSV23 Alone for Reducing Incidence or Severity of Pneumonia in Older Adults? A Clin-IQ

Starla Hayward
Lou Ann Thompson
Andrea McEachern

April 2016

Pneumonia infection is a significant cause of morbidity and mortality worldwide. In addition to the ...

The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly : Exploratory analysis of the CAPiTA trial

Huijts, S. M.
Coenjaerts, F. E.J.
Bolkenbaas, M.
van Werkhoven, C. H.
Grobbee, D. E.
Bonten, M. J.M.

July 2018

Objectives: Our objective was to evaluate whether vaccination with the 13-valent pneumococcal conjug...

Pneumococcal vaccination: what have we learnt so far and what can we expect in the future?

Torres, A.
Bonanni, P.
Hryniewicz, W.
Moutschen, Michel
Reinert, R. R.
Welte, T.

January 2014

Individuals /=50 years of age, as well as those with other specific risk factors, are especially vul...

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

van Deursen, Anna M. M.
van Houten, Marlies A
Webber, Chris
Patton, Michael
Scott, Daniel A.
Patterson, Scott
Sidhu, Mohinder
Drews, Wayne
Gruber, William C.
Emini, Emilio A.
Grobbee, Diederick E.
Bonten, Marc J. M.
Sanders, Elisabeth A. M.

September 2017

Background. In the randomized controlled Community-Acquired Pneumonia Immunization Trial in Adults (...

Immunogenicity of the 13-Valent Pneumococcal Conjugate Vaccine in Older Adults With and Without Comorbidities in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA)

van Deursen, Anna M. M.
van Houten, Marlies A
Webber, Chris
Patton, Michael
Scott, Daniel A.
Patterson, Scott
Sidhu, Mohinder
Drews, Wayne
Gruber, William C.
Emini, Emilio A.
Grobbee, Diederick E.
Bonten, Marc J. M.
Sanders, Elisabeth A. M.

September 2017

Background. In the randomized controlled Community-Acquired Pneumonia Immunization Trial in Adults (...

Pneumococcal disease and vaccinations in older adults

van Deursen, A.M.M.

June 2018

Streptococcus pneumoniae is the most frequently detected human pathogen in respiratory infections wi...

Pneumococcal disease and vaccinations in older adults

van Deursen, A.M.M.

June 2018

Streptococcus pneumoniae is the most frequently detected human pathogen in respiratory infections wi...

Polysaccharide Conjugate Vaccine against Pneumococcal Pneumonia in Adults

Bonten, M. J M
Huijts, S. M.
Bolkenbaas, M.
Webber, C.
Patterson, S.
Gault, S.
Van Werkhoven, C. H.
Van Deursen, A. M M
Sanders, E. A M
Verheij, T. J M
Patton, M.
McDonough, A.
Moradoghli-Haftvani, A.
Smith, H.
Mellelieu, T.
Pride, M. W.
Crowther, G.
Schmoele-Thoma, B.
Scott, D. A.
Jansen, K. U.
Lobatto, R.
Oosterman, B.
Visser, N.
Caspers, E.
Smorenburg, A.
Emini, E. A.
Gruber, W. C.
Grobbee, D. E.

January 2015

BACKGROUND Pneumococcal polysaccharide conjugate vaccines prevent pneumococcal disease in infants, b...

Prevenar 13®, a pneumococcal conjugate vaccine for the prevention of pneumococcal infections in adults at risk

Moutschen, Michel

January 2016

peer reviewedPneumococcal infections remain a major public health issue in aging people. The recent ...

Carriage of Streptoccoccus pneumoniae in healthy adults aged 60 years or over in a population with very high and long-lasting pneumococcal conjugate vaccine coverage in children: rationale and perspectives for PCV13 implementation.

F. Ansaldi
D. d. Florentiis
P. Canepa
A. Ceravolo
E. Rappazzo
R. Iudici
M. Martini
G. Botti
A. Orsi
G. Icardi
P. Durando

January 2013

A serial cross-sectional study of nasopharyngeal carriage among adults aged 60 y or over was conduct...

The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA) : What is the future of pneumococcal conjugate vaccination in elderly?

Van Werkhoven, Cornelis H.
Bonten, Marc Jm

September 2015

Pneumococcal community-acquired pneumonia (PCAP) and invasive pneumococcal disease (IPD) are importa...

The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA) : What is the future of pneumococcal conjugate vaccination in elderly?

Van Werkhoven, Cornelis H.
Bonten, Marc Jm

September 2015

Pneumococcal community-acquired pneumonia (PCAP) and invasive pneumococcal disease (IPD) are importa...

Vaccination status impact on mortality and hospital re-admission for CAP in elderly: a regional italian experience

Baldo, Vincenzo
Cocchio, Silvia
Gallo, T.
Furlan, Patrizia
Bertoncello, Chiara
Baldovin, Tatjana

January 2016

The aim of the study was to evaluate mortality and rehospitalizations after a first episode of Commu...

Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Jackson, Lisa A.
Gurtman, Alejandra
Rice, Kathryn
Pauksens, Karlis
Greenberg, Richard N.
Jones, Thomas R.
Scott, Daniel A.
Emini, Emilio A.
Gruber, William C.
Schmoele-Thoma, Beate

August 2013

AbstractBackgroundThe currently recommended single dose of the 23-valent pneumococcal free polysacch...

The 13-valent pneumococcal conjugated vaccine introduction in subjects aged> 50 years: the result of a Health Technology Assessment

Abstract

Extracted data

The 13-valent pneumococcal conjugated vaccine introduction in subjects aged> 50 years: the result of a Health Technology Assessment

Abstract

Extracted data

Related items

Related items